港股减肥药新贵引爆赛道，A+H股概念股轮番爆发

Group 1 - The core viewpoint of the news highlights the significant market interest in weight loss drugs, particularly following the IPO of Silver诺医药, which saw its market value exceed 26 billion HKD on its first trading day, marking it as one of the hottest IPOs of 2025 [1] - Silver诺医药's IPO was characterized by an oversubscription of 5,341.66 times, with subscription funds amounting to approximately 370 billion HKD, indicating strong investor demand [2] - The company focuses on innovative therapies for metabolic diseases, with its core product, a long-acting GLP-1 receptor agonist, set to launch in China for type 2 diabetes treatment in January 2025, and is currently undergoing clinical trials for obesity [2] Group 2 - Other Hong Kong-listed weight loss concept stocks also experienced significant gains, with派格生物医药 rising 32.45% and 九源基因 and 歌礼制药 both seeing increases of over 10% [1][3] - In the A-share market, companies like 博瑞医药 and 常山药业 have seen their stock prices double this year, reflecting a broader trend of rising interest in weight loss pharmaceuticals [1][3] - The global obesity issue is driving the pharmaceutical industry towards weight loss drugs, with projections suggesting that the GLP-1 drug market could exceed 150 billion USD by 2030, indicating a lucrative opportunity for domestic companies [4]